Results 91 to 100 of about 1,869 (168)

Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis

JAAD International, 2023
Rose Alraddadi, MD, Abdulrahman H. Alsamadani, MD, Mulham A. Kalantan, MD, Yara E. Aljefri, MD, Hadeel A. Maaddawi, MD, Athoub N. Kadasa, MD, Rahaf F. Alturkistani, MD, Abdulhadi H. Jfri, MD, MSc   +7 more
doaj   +1 more source

Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep:results from two Phase III trials in patients with moderate-to-severe atopic dermatitis

Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD.
de Bruin-Weller, Marjolein, Elberling, Jesper, Yosipovitch, Gil, Gutermuth, Jan, Ding, Yuxin, Chisolm, Sarah, Montmayeur, Sonia, Yang, Fan Emily, Pierce, Evangeline, Wiseman, Marni, Bardolet, Laia, Gil Yosipovitch   +11 more
core   +1 more source

A randomised, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).

, 2020
BACKGROUND:The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate to severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess
Kathryn Mesh (4244278), Julie K Olsson (9382694), J Mark FitzGerald (7950029), Miriam Baca (9382682), Gail M Gauvreau (9382685), Elliot Israel (153177), Lief Bjermer (9382691), Joseph R Arron (8946332), John G Matthews (9382709), David F Choy (8946329), Prescott G Woodruff (8950562), Francis Abreu (9382697), Margaret Solon (4495309), Cary D Austin (9382673), Kaharu Sumino (9382688), Fang Cai (48026), Kit Wong (5849114), Ronald E Ferrando (9382679), Wendy S Putnam (9382703), Peter Bradding (60398), Monica Kraft (362538), Arnaud Bourdin (376853), Monet Howard (9382700), Melissa Gonzalez Edick (9382676), Kun Peng (582722), Cécile TJ Holweg (9382706), CLAVIER Investigators (9382712)   +26 more
core  

Lebrikizumab para el tratamiento de la dermatitis atópica

El medicamento Ebglyss® (lebrikizumab-lbkz) recibe el visto bueno tanto de la EMA como de la FDA para tratar los casos de dermatitis atópica de moderada a severa en adultos y adolescentes mayores de 12 años que no remita con otros tratamientos ...
Ruiz-Conca, Mateo
core   +1 more source

Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis

Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD.
Yang, Fan Emily, Wiseman, Marni, Elberling, Jesper, Pierce, Evangeline, Bardolet, Laia, Gutermuth, Jan, Montmayeur, Sonia, de Bruin-Weller, Marjolein, Ding, Yuxin, Chisolm, Sarah, Yosipovitch, Gil   +10 more
core   +2 more sources

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials

Background: Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52.
de Bruin-Weller, Marjolein, Bieber, Thomas, Rosmarin, David, Hong, H. Chih ho, Infection & Immunity, Elmaraghy, Hany, Atwater, Amber Reck, Xu, Chenjia, Guttman-Yassky, Emma, Agell, Helena, MS Dermatologie/Allergologie, Garcia Gil, Esther, Simpson, Eric, Pierce, Evangeline, Weidinger, Stephan   +14 more
core  

Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico. [PDF]

Cureus
Zavala Villafuerte G, Perez-Romero AG, Crocker Sandoval AB.   +2 more
europepmc   +1 more source

Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis". [PDF]

Dermatol Ther (Heidelb)
Rand K, Gebauer K, Binamer Y, Cho YT, Papadimitropoulos M, Yang C, Agell H, Akmaz B, Seminario-Vidal L.   +8 more
europepmc   +1 more source

The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma

US Respiratory & Pulmonary Diseases, 2023
openaire   +1 more source

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2) (Advances in Therapy, (2025), 42, 1, (132-143), 10.1007/s12325-024-02974-y)

The legend for Fig. 4 has published as “Skin improvements in two patients treated with lebrikizumab. a Antecubital fossa and b hand at baseline and at 2, 8, and 16 weeks of lebrikizumab treatment.
de Bruin-Weller, Marjolein, Agell, Helena, Casillas, Marta, Simpson, Eric, Ezzedine, Khaled, Lio, Peter A., Chu, Chia Yu, Ding, Yuxin, Yang, Fan Emily, Bieber, Thomas, Pierce, Evangeline, Fernández-Peñas, Pablo, Infection & Immunity, MS Dermatologie/Allergologie   +13 more
core